These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 25283693)

  • 1. Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser.
    Gao L; Nadora DM; Phan S; Chernova M; Sun V; Preciado SM; Jia W; Wang G; Mihm MC; Nelson JS; Tan W
    Br J Dermatol; 2015 Mar; 172(3):669-76. PubMed ID: 25283693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed ulceration following combination pulse dye laser and topical sirolimus treatment for port wine birthmarks: A case series.
    Hobayan CGP; Nourse EJ; Paradiso MM; Fernandez Faith E
    Pediatr Dermatol; 2024; 41(1):108-111. PubMed ID: 37571864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model.
    Liu C; Tang L; Hou C; Zhang J; Li J
    Clin Cosmet Investig Dermatol; 2023; 16():3023-3034. PubMed ID: 37901151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases.
    Lee JH; An H; Kwon H; Lee SJ; Park YH; Hwang JS; Kim MY; Hwang H; Kim JY; Lee SJ; Chang SE; Song Y
    Clin Transl Med; 2024 Mar; 14(3):e1625. PubMed ID: 38481372
    [No Abstract]   [Full Text] [Related]  

  • 5. A prospective study of risk for Sturge-Weber syndrome in children with upper facial port-wine stain.
    Dutkiewicz AS; Ezzedine K; Mazereeuw-Hautier J; Lacour JP; Barbarot S; Vabres P; Miquel J; Balguerie X; Martin L; Boralevi F; Bessou P; Chateil JF; Léauté-Labrèze C;
    J Am Acad Dermatol; 2015 Mar; 72(3):473-80. PubMed ID: 25592619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
    Gámez-Pozo A; Pérez Carrión RM; Manso L; Crespo C; Mendiola C; López-Vacas R; Berges-Soria J; López IÁ; Margeli M; Calero JL; Farre XG; Santaballa A; Ciruelos EM; Afonso R; Lao J; Catalán G; Gallego JV; López JM; Bofill FJ; Borrego MR; Espinosa E; Vara JA; Zamora P
    PLoS One; 2014; 9(10):e109611. PubMed ID: 25330188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
    Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
    N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial.
    Marqués L; Núñez-Córdoba JM; Aguado L; Pretel M; Boixeda P; Nagore E; Baselga E; Redondo P
    J Am Acad Dermatol; 2015 Jan; 72(1):151-8.e1. PubMed ID: 25455610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser treatment of port-wine stains.
    Brightman LA; Geronemus RG; Reddy KK
    Clin Cosmet Investig Dermatol; 2015; 8():27-33. PubMed ID: 25624768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heredity of port-wine stains: investigation of families without a RASA1 mutation.
    Troilius Rubin A; Lauritzen E; Ljunggren B; Revencu N; Vikkula M; Svensson Å
    J Cosmet Laser Ther; 2015; 17(4):204-8. PubMed ID: 25602354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eczema within port wine stain: spontaneous and laser-induced Meyerson phenomenon.
    Pavlović MD; Adamič M
    Acta Dermatovenerol Alp Pannonica Adriat; 2014; 23(4):81-3. PubMed ID: 25527042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
    Straus DJ; Hamlin PA; Matasar MJ; Lia Palomba M; Drullinsky PR; Zelenetz AD; Gerecitano JF; Noy A; Hamilton AM; Elstrom R; Wegner B; Wortman K; Cella D
    Br J Haematol; 2015 Mar; 168(5):663-70. PubMed ID: 25316653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematoporphyrin monomethyl ether photodynamic therapy for the treatment of facial port-wine stains resistant to pulsed dye laser.
    Zhang M; Wu Q; Lin T; Guo L; Ge Y; Zeng R; Yang Y; Rong H; Jia G; Huang Y; Fang J; Shi H; Zhao W; Chen S; Cai P
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101820. PubMed ID: 32428574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.
    Nguyen V; Hochman M; Mihm MC; Nelson JS; Tan W
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study on clinical operation and post-treatment reactions of HMME-PDT in treatment of PWS.
    Zhang Y; Zou X; Chen H; Yang Y; Lin H; Guo X
    Photodiagnosis Photodyn Ther; 2017 Dec; 20():253-256. PubMed ID: 29079350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological alterations involve the entire skin physiological milieu in infantile and early-childhood port-wine stain.
    Tan W; Zakka LR; Gao L; Wang J; Zhou F; Selig MK; Anvari R; Sukanthanag A; Wang G; Mihm MC; Nelson JS
    Br J Dermatol; 2017 Jul; 177(1):293-296. PubMed ID: 27639180
    [No Abstract]   [Full Text] [Related]  

  • 19. Port wine stain treated with a combination of pulsed dye laser and topical rapamycin ointment.
    Griffin TD; Foshee JP; Finney R; Saedi N
    Lasers Surg Med; 2016 Feb; 48(2):193-6. PubMed ID: 26503090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly Pulsed Dye Laser Treatments for Port-Wine Birthmarks in Infants.
    Bajaj S; Tao J; Hashemi DA; Geronemus RG
    JAMA Dermatol; 2024 Jun; 160(6):606-611. PubMed ID: 38630490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.